Full-Time

Quality Assurance Specialist 1

ANI Pharmaceuticals

ANI Pharmaceuticals

501-1,000 employees

Develops, manufactures, markets prescription drugs

Compensation Overview

$54k - $78k/yr

Baudette, MN, USA

In Person

Occasional travel is required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Quality Assurance (QA)

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Requirements
  • A Bachelor's degree and 2 years of experience working within Quality Assurance or Quality Control are required.
  • A good understanding of laboratory testing and raw data, particularly High-Performance Liquid Chromatography, is required.
  • Previous work in a regulated environment is required.
  • Knowledge of current Good Manufacturing Practices is required.
  • The ability to read and follow procedures is required.
  • The ability to coordinate multiple tasks in a fast-paced environment is required.
  • The ability to work independently and within a team environment is required.
  • Problem-solving skills and attention to detail are required.
  • Computer skills, organizational and follow-through skills, interpersonal skills, and written and verbal communication skills are required.
  • Occasional travel is required.
Responsibilities
  • Assure the quality of documentation and data and assign disposition of batch records for raw materials, packaging components, finished product release, and stability documents.
  • Provide support to Manufacturing and Packaging operations to ensure relevant procedures are followed and meet current Good Manufacturing Practices requirements.
  • Review notebooks, data sheets, electronic data, ancillary data, logbooks, and reports of results for compliance with corporate Standard Operating Procedures and Food and Drug Administration guidelines.
  • Highlight Good Manufacturing Practice deficiencies, initiate the required documentation process, facilitate corrective actions, and monitor resolution.
  • Assist the stability department, validation activities, and annual report assembly as required.
  • Perform disposition of finished products, raw materials, and packaging components.
  • Review finished product stability data.
  • Perform packaging-line inspections and audits and provide assurance that packaging operations comply with applicable Standard Operating Procedures and current Good Manufacturing Practices.
  • Perform finished-product attribute sample inspections and evaluate the physical characteristics of finished products before packaging.
  • Perform annual retain-sample inspections and control finished-product and raw-material retain samples stored in the reserve sample room.
  • Monitor Good Manufacturing Practice areas for compliance with requirements such as proper gowning and cleanliness under 21 CFR Subpart A, General Provisions.
  • Perform other duties as assigned or requested.

ANI Pharmaceuticals develops, manufactures, and markets prescription medications, including generic and branded products, that are FDA-approved. Its medicines are produced in regulated facilities and go through standard safety and efficacy testing to meet patient needs. The company sells these products to pharmacies, hospitals, and healthcare providers, using a portfolio that spans generic drugs and specialty branded therapies. What sets ANI apart is its combination of a diversified product lineup with growth through strategic acquisitions to expand its offerings and market reach, rather than relying on a single product area. Its goal is to provide high-quality medicines to patients while continuously expanding its portfolio and market presence through acquisitions and manufacturing capabilities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Baudette, Minnesota

Founded

1996

Get referred to ANI Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $266 million, and management reaffirmed $1.08-$1.14 billion guidance.
  • July 2026 was the highest month for new Cortrophin cases, signaling demand acceleration.
  • Repurchased-capable cash generation reached $360.2 million, funding acquisitions and buybacks through May 2029.

What critics are saying

  • Cortrophin 2026 guidance fell to $520-$540 million, exposing second-half execution risk.
  • Merck royalty burden stays in the high-20% range, compressing Cortrophin margins.
  • CG Oncology litigation still lingers after the July 29, 2025 no-damages verdict, risking distraction.

What makes ANI Pharmaceuticals unique

  • Cortrophin Gel drove 43.5% Q2 2026 growth, with rare disease becoming ANI's core.
  • ANI pairs U.S. manufacturing with 116 products, supporting branded, generic, and specialty breadth.
  • Henry Gosebruch joined August 19, 2026, bringing AbbVie M&A discipline to transformation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

23%
Yahoo Finance
Aug 28th, 2026
ANI Pharmaceuticals shows 36% revenue growth but limited scale at $978M

ANI Pharmaceuticals trades at $76.15 per share, showing a 3% return over six months, underperforming the S&P 500's 11.7% gain. The company develops, manufactures, and markets branded and generic prescription pharmaceuticals with a portfolio of 116 products. The pharmaceutical firm demonstrated strong momentum with revenue growing at 35.6% compound annual growth rate over five years. Its free cash flow margin expanded by 38.5 percentage points during the same period, reaching 17.7% over the trailing 12 months. However, ANI Pharmaceuticals faces scale challenges with just $978.4 million in revenue over the past year. This smaller size limits its ability to build customer trust in the heavily regulated healthcare sector, though it allows for faster potential growth with proper execution.

Yahoo Finance
Aug 24th, 2026
ANI Pharmaceuticals targets $1.6B market cap with 34.7% revenue growth, while Revolve and ProPetro face challenges

ANI Pharmaceuticals, a developer and marketer of branded and generic prescription drugs with a focus on rare disease treatments, stands out among Russell 2000 stocks. The company's portfolio includes 116 pharmaceutical products. ANI delivered 34.7% annual revenue growth over the past two years, indicating market share gains. Earnings per share increased 19.9% annually over five years, outperforming peers. The company's free cash flow margin improved by 38.5 percentage points over five years, providing resources for growth initiatives, share buybacks, or dividends. Meanwhile, fashion retailer Revolve and hydraulic fracturing services provider ProPetro face challenges. Revolve's 6.6% annual sales growth and 6.5% customer growth over three years underperformed, whilst high marketing expenses suggest heavy spending on customer acquisition. ProPetro's modest revenue base and declining EBITDA margin limit its competitiveness.

Yahoo Finance
Aug 24th, 2026
ANI Pharmaceuticals appoints Henry Gosebruch to board amid rare disease company transformation

ANI Pharmaceuticals has appointed Henry Gosebruch to its board of directors, effective 19 August 2026. Gosebruch brings over 30 years of experience in corporate strategy, business development, and finance across the biopharmaceutical sector. He currently serves as chief executive officer of Lakefront Biotherapeutics and previously held leadership positions at Neumora Therapeutics and AbbVie, where he oversaw more than 100 transactions including AbbVie's acquisition of Allergan. Before that, he spent over 20 years at J.P. Morgan as co-head of North American M&A. The appointment aims to strengthen ANI's board as the company accelerates its transformation into a rare disease-focused business. Muthusamy Shanmugam has resigned from the board but will continue as head of research and development and chief operating officer of New Jersey operations.

Yahoo Finance
Aug 16th, 2026
ANI Pharmaceuticals beats Q2 estimates with $266M revenue despite market concerns over Cortrophin guidance

ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million with 25.9% year-on-year growth. The company's adjusted EPS of $2.21 also surpassed expectations of $2.04. Despite strong performance in rare disease and generics businesses, the market reacted negatively to the results. CEO Nikhil Lalwani highlighted momentum in the third quarter, noting July marked the highest month for new cases initiated. The company reconfirmed its full-year revenue guidance of $1.11 billion at the midpoint and maintained its adjusted EPS guidance of $9.44. Operating margin improved to 15.2%, up from 6.6% in the same quarter last year. Analysts questioned the disconnect between prescription data and revenue, insurance reverification issues, and the rationale behind lowering Cortrophin guidance despite positive demand metrics.

Yahoo Finance
Aug 15th, 2026
ANI Pharmaceuticals posts 26% revenue growth but shares fall 9% on weak guidance

ANI Pharmaceuticals reported Q2 revenues of $266 million, up 25.9% year on year, exceeding analyst expectations by 2.4%. The company beat EPS estimates but slightly missed full-year revenue guidance expectations. Despite posting the fastest revenue growth among the four generic pharmaceuticals stocks tracked, ANI's shares fell 9.1% following the results. The company's portfolio includes 116 pharmaceutical products with a focus on rare disease treatments. Generic pharmaceuticals companies as a group delivered strong Q2 results, with revenues beating consensus estimates by 2.6%. However, the sector has struggled recently, with share prices down 5.6% on average since the latest earnings announcements. The industry faces pricing pressures and thin margins but benefits from consistent demand for affordable medications.